PROQR THERAPEUTICS EO-04 (0PQ) - Total Liabilities
Based on the latest financial reports, PROQR THERAPEUTICS EO-04 (0PQ) has total liabilities worth €63.38 Million EUR (≈ $74.10 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is PROQR THERAPEUTICS EO-04 growing its equity to track the company's year-over-year net asset growth rate.
PROQR THERAPEUTICS EO-04 - Total Liabilities Trend (2021–2025)
This chart illustrates how PROQR THERAPEUTICS EO-04's total liabilities have evolved over time, based on quarterly financial data. See PROQR THERAPEUTICS EO-04 (0PQ) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
PROQR THERAPEUTICS EO-04 Competitors by Total Liabilities
The table below lists competitors of PROQR THERAPEUTICS EO-04 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Major Cineplex Group Public Company Limited
BK:MAJOR
|
Thailand | ฿7.58 Billion |
|
Hana Financial 7 SPAC
KQ:230240
|
Korea | ₩114.84 Billion |
|
S&P Syndicate Public Company Limited
BK:SNP
|
Thailand | ฿1.52 Billion |
|
Tung Thih Electronic Co Ltd
TWO:3552
|
Taiwan | NT$6.26 Billion |
|
Calin Technology Co Ltd
TW:4976
|
Taiwan | NT$377.35 Million |
|
Tonlin Department Store Co Ltd
TW:2910
|
Taiwan | NT$3.48 Billion |
|
Asian Hotels (North) Limited
NSE:ASIANHOTNR
|
India | Rs12.92 Billion |
|
Sungei Bagan Rubber Malaya
KLSE:2569
|
Malaysia | RM17.53 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down PROQR THERAPEUTICS EO-04's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 0PQ market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.56 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PROQR THERAPEUTICS EO-04's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PROQR THERAPEUTICS EO-04 (2021–2025)
The table below shows the annual total liabilities of PROQR THERAPEUTICS EO-04 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €63.38 Million ≈ $74.10 Million |
-20.17% |
| 2024-12-31 | €79.40 Million ≈ $92.82 Million |
-17.72% |
| 2023-12-31 | €96.49 Million ≈ $112.81 Million |
-7.79% |
| 2022-12-31 | €104.64 Million ≈ $122.34 Million |
+8.60% |
| 2021-12-31 | €96.35 Million ≈ $112.64 Million |
-- |
About PROQR THERAPEUTICS EO-04
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic disea… Read more